

AMENDMENT
U.S. Appln. No.

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in this application:

Listing of Claims:

1. (Currently amended) An inhalable powder comprising 0.04 to 0.8% of tiotropium in admixture with a physiologically acceptable excipient, wherein the excipient consists of a mixture of coarser excipient with an average particle size of 15 to 80 μm and finer excipient with an average particle size of 1 to 9 μm , the proportion of the finer excipient constituting 1 to

20% of the total amount of excipient, wherein the inhalable proportion of active substance is released reproducibly in low variability amounts when administered to a patent.

2. (previously presented) An inhalable powder according to claim 1, wherein the tiotropium is present in the form of the chloride, bromide, iodide, methanesulphonate, para-toluenesulphonate or methyl sulphate thereof.

3. (Currently amended) An inhalable powder comprising between 0.048 and 0.96% of tiotropium bromide in admixture with a physiologically acceptable excipient, wherein the excipient consists of a mixture of coarser excipient with an average particle size of 15 to 80 μm and finer excipient with an average particle size of 1 to 9 μm , the proportion of the finer

excipient constituting 1 to 20% of the total amount of excipient, wherein the inhalable proportion of active substance is released reproducibly in low variability amounts when administered to a patent.

AMENDMENT
U.S. Appln. No.

4. (Currently amended) An inhalable powder comprising between 0.05 and 1% of tiotropium bromide monohydrate in admixture with a physiologically acceptable excipient, wherein the excipient consists of a mixture of coarser excipient with an average particle size of 15 to 80 μm and finer excipient with an average particle size of 1 to 9 μm , the proportion of the finer

excipient constituting 1 to 20% of the total amount of excipient, wherein the inhalable proportion of active substance is released reproducibly in low variability amounts when administered to a patient.

5. (previously presented) An inhalable powder according to one of claims 1, 2, 3 or 4, wherein the excipient consists of a mixture of coarser excipient with an average particle size of 17 to 50 μm and finer excipient with an average particle size of 2 to 8 μm .

6. (previously presented) An inhalable powder according to one of claims 1, 2, 3 or 4, wherein the proportion of finer excipient in the total amount of excipient is 3 to 15%.

7. (previously presented) An inhalable powder according to one of claims 1, 2, 3 or 4, wherein the tiotropium used has an average particle size of 0.5 to 10 μm .

8. (previously presented) An inhalable powder according to one of claims 1, 2, 3 or 4, wherein one or more monosaccharides, disaccharides, oligo- or polysaccharides, polyalcohols, salts thereof, or mixtures thereof are used as the excipients.

9. (previously presented) An inhalable powder according to claim 8, wherein glucose, arabinose, lactose, saccharose, maltose, dextrane, sorbitol, mannitol, xylitol, sodium chloride,

AMENDMENT
U.S. Appln. No.

calcium carbonate or mixtures thereof are used as the excipients.

10. (previously presented) An inhalable powder according to claim 9, wherein glucose or lactose or mixtures thereof are used as the excipients.

11. (original) A process for preparing an inhalable powder according to one of claims 1 to 4, comprising: (a) mixing coarser excipient fractions with finer excipient fractions to obtain an excipient mixture, and (b) mixing the excipient mixture thus obtained with the tiotropium.

12. (cancelled)

13. (original) A method of treating a disease that is responsive to the administration of tiotropium, comprising administering to a host in need thereof an inhalable powder according to one of claims 1 to 4 or 12.

14. (original) A method according to claim 13, wherein the disease is asthma or COPD.

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (previously presented) An inhalable powder according to claim 4 comprising 0.1 to 0.8% of tiotropium bromide monohydrate.

AMENDMENT
U.S. Appln. No.

19. (previously presented) An inhalable powder according to claim 4 comprising 0.2 to 0.5% of tiotropium bromide monohydrate.

20. (previously presented) An inhalable powder according to one of claims 1, 2, 3 or 4, wherein the excipient consists of a mixture of coarser excipient with an average particle size of 20 to 30 μm and finer excipient with an average particle size of 3 to 7 μm .

21. (previously presented) An inhalable powder according to one of claims 1, 2, 3 or 4, wherein the proportion of finer excipient in the total amount of excipient is 5 to 10%.

22. (previously presented) An inhalable powder according to one of claims 1, 2, 3 or 4, wherein the tiotropium used has an average particle size of 1 to 6 μm .

23. (previously presented) An inhalable powder according to one of claims 1, 2, 3 or 4, wherein the tiotropium used has an average particle size of 2 to 5 μm .

24. (previously presented) An inhalable powder according to claim 10, wherein lactose monohydrate is used as the excipient.

25. (Currently amended) An inhalable powder comprising between 0.2 and 0.5% of tiotropium bromide monohydrate in admixture with lactose monohydrate as the physiologically acceptable excipient, wherein the excipient consists of a mixture of coarser excipient with an average particle size of 20 to 30 μm and finer excipient with an average particle size of 3 to 7 μm , the proportion of the finer excipient constituting 5 to 10% of the total amount of excipient, wherein the inhalable proportion of active substance is released reproducibly in low variability amounts when administered to a patient.

AMENDMENT
U.S. Appln. No.

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)

31. (Cancelled)

32. (Currently amended) An inhalable powder comprising 0.04 to 0.8% of tiotropium in admixture with a physiologically acceptable excipient, said inhalable powder prepared by a process comprising: (a) mixing coarser excipient having an average particle size of 15 to 80 μm and finer excipient having an average particle size of 1 to 9 μm , wherein the proportion of the finer excipient constitutes 1 to 20% of the total amount of excipient, to obtain an excipient mixture, and (b) mixing the excipient mixture thus obtained with the tiotropium, wherein the inhalable proportion of active substance is released reproducibly in low variability amounts when administered to a patient.

33. (previously presented) An inhalable powder according to claim 32, wherein the tiotropium is present in the form of the chloride, bromide, iodide, methanesulphonate, para-toluenesulphonate or methyl sulphate thereof.

34. (Currently amended) An inhalable powder comprising between 0.048 and 0.96% of tiotropium bromide in admixture with a physiologically acceptable excipient, said inhalable powder prepared by a process comprising: (a) mixing coarser excipient having an average

AMENDMENT
U.S. Appln. No.

particle size of 15 to 80 μm and finer excipient having an average particle size of 1 to 9 μm , wherein the proportion of the finer excipient constitutes 1 to 20% of the total amount of excipient, to obtain an excipient mixture, and (b) mixing the excipient mixture thus obtained with the tiotropium bromide, wherein the inhalable proportion of active substance is released reproducibly in low variability amounts when administered to a patent.

35. (Currently amended) An inhalable powder comprising between 0.05 and 1% of tiotropium bromide monohydrate in admixture with a physiologically acceptable excipient, said inhalable powder prepared by a process comprising: (a) mixing coarser excipient having an average particle size of 15 to 80 μm and finer excipient having an average particle size of 1 to 9 μm , wherein the proportion of the finer excipient constitutes 1 to 20% of the total amount of excipient, to obtain an excipient mixture, and (b) mixing the excipient mixture thus obtained with the tiotropium bromide monohydrate, wherein the inhalable proportion of active substance is released reproducibly in low variability amounts when administered to a patent.

36. (previously presented) An inhalable powder according to claim 35 comprising 0.1 to 0.8% of tiotropium bromide monohydrate.

37. (previously presented) An inhalable powder according to claim 35 comprising 0.2 to 0.5% of tiotropium bromide monohydrate.

38. (previously presented) An inhalable powder according to one of claims 32, 33, 34 or 35, wherein the coarser excipient has an average particle size of 17 to 50 μm and the finer excipient has an average particle size of 2 to 8 μm .

AMENDMENT
U.S. Appln. No.

39. (previously presented) An inhalable powder according to one of claims 32, 33, 34 or 35, wherein the coarser excipient has an average particle size of 20 to 30 μm and the finer excipient has an average particle size of 3 to 7 μm .

40. (previously presented) An inhalable powder according to one of claims 32, 33, 34 or 35, wherein the proportion of finer excipient in the total amount of excipient is 3 to 15%.

41. (previously presented) An inhalable powder according to one of claims 32, 33, 34 or 35, wherein the proportion of finer excipient in the total amount of excipient is 5 to 10%.

42. (previously presented) An inhalable powder according to one of claims 32, 33, 34 or 35, wherein the tiotropium used has an average particle size of 0.5 to 10 μm .

43. (previously presented) An inhalable powder according to one of claims 32, 33, 34 or 35, wherein the tiotropium used has an average particle size of 1 to 6 μm .

44. (previously presented) An inhalable powder according to one of claims 32, 33, 34 or 35, wherein the tiotropium used has an average particle size of 2 to 5 μm .

45. (previously presented) An inhalable powder according to one of claims 32, 33, 34 or 35, wherein one or more monosaccharides, disaccharides, oligo- or polysaccharides, polyalcohols, salts thereof, or mixtures thereof are used as the excipients.

46. (previously presented) An inhalable powder according to claim 45, wherein glucose, arabinose, lactose, saccharose, maltose, dextrane, sorbitol, mannitol, xylitol, sodium chloride, calcium carbonate or mixtures thereof are used as the excipients.

AMENDMENT
U.S. Appln. No.

47. (previously presented) An inhalable powder according to claim 46, wherein glucose or lactose or mixtures thereof are used as the excipients.
48. (previously presented) An inhalable powder according to claim 47, wherein lactose monohydrate is used as the excipient.
49. (Currently amended) An inhalable powder comprising between 0.2 and 0.5% of tiotropium bromide monohydrate in admixture with lactose monohydrate as a physiologically acceptable excipient, said inhalable powder prepared by a process comprising: (a) mixing coarser lactose monohydrate excipient having an average particle size of 20 to 30 μm and finer lactose monohydrate excipient having an average particle size of 3 to 7 μm , wherein the proportion of the finer lactose monohydrate excipient constitutes 5 to 10% of the total amount of excipient, to obtain an excipient mixture, and (b) mixing the excipient mixture thus obtained with the tiotropium bromide monohydrate, wherein the inhalable proportion of active substance is released reproducibly in low variability amounts when administered to a patient.
50. (previously presented) A method of treating a disease that is responsive to the administration of tiotropium, comprising administering to a host in need thereof an inhalable powder according to one of claims 32, 33, 34 or 35 or 49.
51. (previously presented) A method according to claim 50, wherein the disease is asthma or COPD.
52. (Cancelled)

AMENDMENT
U.S. Appln. No.

53. (Cancelled)

54. (Cancelled)

55. (Cancelled)

56. (Cancelled)

57. (Cancelled)

58. (Cancelled)

|